Announced details
Clarification of the mechanisms of aging, research into various diseases, clinical research, supplement and functional product development, and personalized healthcare
Blood samples can be sent by refrigerated transport rather than frozen transport. NAD+ can be quantified with high sensitivity from a very small blood sample.
The Company holds patent rights to the DBS method, but the number and expiration date are Not disclosed
The impact on our financial results is minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Blood NAD+ High-Sensitivity Quantitative Analysis Service |
| Launch date | 31 July 2026 (sales launch, actual) |
| Applicable area | Clarification of the mechanisms of aging, research into various diseases, clinical research, supplement and functional product development, and personalized healthcare |
| Registration number and expiry date | The Company holds patent rights to the DBS method, but the number and expiration date are Not disclosed |
| Quantitative Effects | Blood samples can be sent by refrigerated transport rather than frozen transport. NAD+ can be quantified with high sensitivity from a very small blood sample. |
| Impact on Business Performance | The impact on our financial results is minor. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To address sample instability in NAD+ measurement and the need for strict freezing and frozen transport under conventional methods, thereby simplifying measurement for clinical research and the healthcare sector.